Insights

Our Progress

Biomeme to Receive Portion of $21 Million Investment for Molecular Diagnostic Testing in LMICs

FIND, the global alliance for diagnostics, announced on December 20, 2021 a US$21 million investment to accelerate the development, manufacturing, and launch of affordable, multi-pathogen, molecular...

Read More

Search By Topic

Get the latest tips from Biomeme shipped right to your inbox

Product Updates

What We Know About Omicron Variant

Through in silico analysis, we’ve confirmed Biomeme’s SARS-Cov-2 assay detects all current variants of concern and variants of interest including delta and omicron. Omicron was first identified in...

Read More
Our Progress

Event Recap: 2021 Nucleus Awards Presented by the University City Science Center

Each year, the University City Science Center’s Nucleus Awards bring together the region’s leaders and groundbreakers in innovation, all while supporting Philadelphia’s future as a hub of innovation...

Read More
Our Approach

Biomeme & Predigen Merge to Enable Point-of-Care Delivery of Host Response Tests That Address Critical Unmet Needs in Healthcare

Biomeme is excited to announce that we have signed a definitive agreement to acquire Predigen, a spin-out from Duke University and global leader in the development of host gene expression signatures...

Read More
Our People

A First Look Inside the New Biomeme Corporate Headquarters

Biomeme’s move into its new corporate headquarters at Netrality's 401 North Broad Street, will begin an exciting new chapter for our company. Our new headquarters were announced earlier this year and...

Read More
Product Updates

Biomeme's SARS-CoV-2 Test Authorized for Emergency Use with Pooled Samples by FDA

We are pleased to announce that the U.S. Food and Drug Administration (FDA) amended Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use with pooled samples in...

Read More
Product Explainers

What Type of COVID-19 Test is Right for Me?

This is a very common question, so let’s get straight to it. There are 2 kinds of tests available for COVID-19: Direct Detection - tells you if portions of the SARS-CoV-2 virus were detected in your...

Read More
Our Progress

Event Recap: U.S. Department of Homeland Security Centers of Excellence Summit 2021

With support from the Cross-Border Threat Screening and Supply Chain Defense Center of Excellence, Biomeme and Predigen were proud to recently participate in discussion and demonstration of our work...

Read More
Product Updates

Introducing SARS-CoV-2 Mutation Panel 1.0 by Biomeme

EDIT: As RNA viruses like SARS-CoV-2 continue to mutate, so will this panel. Please review our COVID-19 page for the latest information regarding our testing capabilities, including variant/mutation...

Read More
Our People

Biomeme to Open New Headquarters at Netrality’s 401 North Broad 🍾

Biomeme has officially outgrown its home at 10th and Chestnut and is moving on to Netrality’s 401 North Broad Street for its new corporate headquarters! The new headquarters boasts 44,000 square feet...

Read More
Prev 2 3 4 5 6 Next